[关键词]
[摘要]
目的 探讨康艾注射液联合西妥昔单抗治疗晚期结直肠癌的临床疗效。方法 选取2016年1月-2017年1月于青岛市商业职工医院进行治疗的晚期结直肠癌患者76例,根据治疗方案的差别分为对照组(38例)和治疗组(38例)。对照组患者静脉滴注西妥昔单抗注射液,初始剂量为400 mg/(m2·周),滴速≤ 5 mL/min,滴注时间120 min,然后维持250 mg/(m2·周)。治疗组在对照组的基础上静脉滴注康艾注射液,40 mL加入5%葡萄糖注射液250 mL,1次/d。两组患者均治疗6周。评价两组患者临床疗效,同时比较治疗前后两组患者生存质量改善情况、血清学指标和不良反应情况。结果 治疗后,对照组的客观缓解率(ORR)和临床获益率(CBR)分别为28.95%%、52.63%,均分别显著低于治疗组的50.00%、73.68%,两组比较差异均具有统计学意义(P<0.05)。治疗后,对照组改善率为68.42%,显著低于治疗组的92.11%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血清血管内皮生长因子(VEGF)、缺氧诱导因子-1α(HIF-1α)和基质金属蛋白酶-9(MMP-9)水平明显降低,而IL-2和干扰素-γ(IFN-γ)水平明显增高,同组比较差异具有统计学意义(P<0.05);且治疗组上述指标改善情况明显优于对照组,两组比较差异具有统计学意义(P<0.05)。结论 康艾注射液联合西妥昔单抗可有效提高晚期结直肠癌患者机体免疫功能,并可显著改善患者生活质量,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To investigate the clinical efficacy of Kang'ai Injection combined with cetuximab in treatment of advanced colorectal cancer. Methods Patients (76 cases) with advanced colorectal cancer in Qingdao Commercial Staff Hospital from January 2016 to January 2017 were divided into control (38 cases) and treatment (38 cases) groups based on different treatments. Patients in the control group were iv administered with Cetuximab Solution for infusion, the initial dosage was 400 mg/(m2·week), the speed ≤ 5 mL/min, and the drip time was 120 min, then maintained the speed at 250 mg/(m2·week). Patients in the treatment group were iv administered with Kang'ai Injection on the basis of the control group, 40 mL added into 5% glucose injection 250 mL, once daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the improvement of life quality, serological indexes and adverse reactions in two groups before and after treatment were compared. Results After treatment, ORR and CBR in the control group were 28.95%% and 52.63%, which were significantly lower than 50.00% and 73.68% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the improvement rate in the control group was 68.42%, which was significantly lower than 92.11% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the VEGF, HIF-1α and MMP-9 levels in two groups were significantly decreased, but IL-2 and IFN-γ levels were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the improvement of these indexes in the treatment group was significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Kang'ai Injection combined with cetuximab can improve the immunity in treatment of advanced colorectal cancer, and can effectively improve the quality of life, which has a certain clinical application value.
[中图分类号]
[基金项目]